![Olivier Martinez](/newimages/folsm/person-profile/scps/olivier-martinez.x3002681f.png?f=webp)
Biography
Dr Olivier Martinez is a Research Associate in the Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences.
He is a researcher in cell-based therapy with an academic background in molecular biology and biochemistry. His main focus is the generation of CAR T cell products able to circumvent the immunosuppressive microenvironment encountered in solid tumours.
Research
![car mechanics RG thumbnail](/newimages/folsm/hero-banner/scps/car-mechanics-rg-thumbnail.x51fbea40.png?width=380&height=215&fit=crop&f=webp)
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.
Research
![car mechanics RG thumbnail](/newimages/folsm/hero-banner/scps/car-mechanics-rg-thumbnail.x51fbea40.png?width=380&height=215&fit=crop&f=webp)
CAR Mechanics Group
The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.